{
    "clinical_study": {
        "@rank": "104372", 
        "arm_group": [
            {
                "arm_group_label": "bimatoprost", 
                "description": "These patients take bimatoprost topically for glaucoma."
            }, 
            {
                "arm_group_label": "latanoprost group", 
                "description": "These patients take latanoprost topically for glaucoma."
            }
        ], 
        "biospec_descr": {
            "textblock": "Note patients will be recruited to fill out a questionnaire, describing their symptoms\n      related to glaucoma use drops.  In this study, we are examining only patients taking either\n      bimatoprost or latanoprost, thus 2 cohorts. However, this is not an interventional study,\n      and there will be only one study visit (enrollment and questionnaire at the same time) and\n      no change in the patient's prescribed therapy."
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "This study examines patient perceptions regarding the tolerability of two classes of\n      glaucoma medication:  bimatoprost and latanoprost."
        }, 
        "brief_title": "Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glaucoma", 
        "condition_browse": {
            "mesh_term": "Glaucoma"
        }, 
        "detailed_description": {
            "textblock": "Patients enrolled in this study completed a validated survey instrument (COMTOL) examining\n      tolerability of topically applied ophthalmic medications that they are already taking in\n      their regular course of care for glaucoma.  The purpose of the study is to determine whether\n      side effects and symptoms of the drugs already being taken cause problems with activities of\n      daily living."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with glaucoma taking either bimatoprost or latanoprost\n\n        Exclusion Criteria:\n\n          -  patients taking other medication or with other causes for ocular surface symptoms"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients taking either study medication for glaucoma."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138461", 
            "org_study_id": "JH-ALG-MDB-1301"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Latanoprost", 
                "Bimatoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glaucoma", 
            "bimatoprost", 
            "latanoprost", 
            "tolerability"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Carol Hardy", 
                "phone": "949-951-2020"
            }, 
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92653"
                }, 
                "name": "Harvard Eye Associates"
            }, 
            "investigator": [
                {
                    "last_name": "Savak Teymoorian, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John A Hovanesian, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.", 
        "overall_contact": {
            "email": "chardy@harvardeye.com", 
            "last_name": "Carol Hardy, BS", 
            "phone": "949 900 5248"
        }, 
        "overall_official": [
            {
                "affiliation": "UCLA Jules Stein Eye Institute", 
                "last_name": "John A. Hovanesian, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Harvard Eye Associates", 
                "last_name": "Savak Teymoorian, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice.  Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.", 
            "measure": "Tolerability of medications as measured by the COMTOL validated instrument", 
            "safety_issue": "No", 
            "time_frame": "at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MDbackline, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "MDbackline, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}